Qiming Venture Partners

Windward Bio shares close 68% above $17 IPO price on Nasdaq debut

SHANGHAI -- November 16, 2026 -- Windward Bio, a clinical-stage biotechnology company founded in 2024, closed its first Nasdaq trading day on November 13, 2026 at $28.50 per share, 68% above its $17.00 IPO price. The $11.50 gain per share lifted the company's market capitalization to about $1.69 billion, against roughly $1.01 billion at the offer price by our calculation.

The $1.69 billion figure works out to about 59 million shares ($1.69 billion divided by $28.50), assuming the release values the company at the closing price. The company trades as WWB. It did not disclose the gross proceeds of the offering.

Qiming Venture Partners backed Windward Bio from Series A through the IPO

Qiming Venture Partners invested in Windward Bio's Series A in 2025 and its Series B in 2026, and it took part in the IPO round. The listing is Qiming's 11th IPO in 2026. Windward Bio reached the public market about two years after its 2024 founding.

S2S China Names 10 Biotech Finalists for Westlake Pitch Event

Image
S2S China Names 10 Biotech Finalists for Westlake Pitch Event

Shanghai – – September 21, 2026 -- Ten biotech startup teams have been selected as finalists for the inaugural S2S China Symposium, narrowed from roughly 20 semifinalists who competed to pitch global venture investors at Westlake University on October 15.

RA Capital and Qiming Venture Partners co-host China chapter of Science2Startup

S2S China is the China chapter of Science2Startup, an invitation-only program founded in 2018 by F-Prime, SV Health and Atlas Venture that connects academic therapeutics researchers with biotech investors. RA Capital Management, Osage University Partners and 5AM Ventures have since joined the network. The China edition is co-hosted by RA Capital Management and Qiming Venture Partners.